2023 changes to FIGO endometrial cancer staging: Counterpoint

•Cancer staging is an important prognostic criterion and should remain anatomic. •Histology should not be dichotomized and should not be a part of staging. •Diagnosis/quantification of LVSI is debatable and should not be a part of staging. •Molecular-based prognostication is evolving and should not be a part of staging. •The FIGO 2023 staging system is complex and will lead to confusing data outcomes.